Overview

FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease

Status:
Completed
Trial end date:
2017-06-14
Target enrollment:
Participant gender:
Summary
This is a randomized, multicenter, open-label, active-controlled study of the treatment of anemia in subjects with CKD on dialysis, with treatment up to 52 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
FibroGen
Treatments:
Epoetin Alfa